Dennis Choi, MD | PhD


Dr. Dennis Choi is Professor of Neurology at Stony Brook University, having previously worked as Director of the Brain Science Institute at the Korea Institute of Science and Technology, Executive Vice President at the Simons Foundation, Vice President for Academic Health Affairs at Emory University, Executive Vice President for Neuroscience at Merck Research Labs, and Head of Neurology at Washington University.

Dr. Choi received his M.D. from the Harvard-MIT Health Sciences and Technology Program, as well as a Ph.D. in pharmacology and neurology residency training at Harvard. A fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine, he has served as President of the Society for Neuroscience, Vice-President of the American Neurological Association, and chairman of the U.S./Canada Regional Committee of the International Brain Research Organization.

He has been a member of the Board on Life Sciences of the National Academy of Sciences; the Nervous System Drugs Advisory Committee to the U.S. Food & Drug Administration; and Councils for the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the Winter Conference for Brain Research, the International Society for Cerebral Blood Flow and Metabolism, and the Neurotrauma Society; as well as the advisory boards of multiple non-profit disease foundations and companies.

He has been a pioneer in developing the field of neuroprotection: identifying mechanisms responsible for nervous system injury in disease states, especially ischemia and trauma, and developing therapeutic countermeasures.

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.